247 related articles for article (PubMed ID: 21224362)
21. Molecular basis for the interaction of the hepatitis B virus core antigen with the surface immunoglobulin receptor on naive B cells.
Lazdina U; Cao T; Steinbergs J; Alheim M; Pumpens P; Peterson DL; Milich DR; Leroux-Roels G; Sällberg M
J Virol; 2001 Jul; 75(14):6367-74. PubMed ID: 11413303
[TBL] [Abstract][Full Text] [Related]
22. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
23. Antibodies elicited by naked DNA vaccination against the complementary-determining region 3 hypervariable region of immunoglobulin heavy chain idiotypic determinants of B-lymphoproliferative disorders specifically react with patients' tumor cells.
Rinaldi M; Ria F; Parrella P; Signori E; Serra A; Ciafrè SA; Vespignani I; Lazzari M; Farace MG; Saglio G; Fazio VM
Cancer Res; 2001 Feb; 61(4):1555-62. PubMed ID: 11245465
[TBL] [Abstract][Full Text] [Related]
24. Immunogenicity and efficacy of two types of West Nile virus-like particles different in size and maturation as a second-generation vaccine candidate.
Ohtaki N; Takahashi H; Kaneko K; Gomi Y; Ishikawa T; Higashi Y; Kurata T; Sata T; Kojima A
Vaccine; 2010 Sep; 28(40):6588-96. PubMed ID: 20678586
[TBL] [Abstract][Full Text] [Related]
25. Prevention of mammary tumors with a chimeric HER-2 B-cell epitope peptide vaccine.
Dakappagari NK; Douglas DB; Triozzi PL; Stevens VC; Kaumaya PT
Cancer Res; 2000 Jul; 60(14):3782-9. PubMed ID: 10919651
[TBL] [Abstract][Full Text] [Related]
26. Development of HIV/AIDS vaccine using chimeric gag-env virus-like particles.
Kang CY; Luo L; Wainberg MA; Li Y
Biol Chem; 1999 Mar; 380(3):353-64. PubMed ID: 10223338
[TBL] [Abstract][Full Text] [Related]
27. High immunogenicity of a hydrophilic component of the hepatitis B virus preS1 sequence exposed on the surface of three virus-like particle carriers.
Skrastina D; Bulavaite A; Sominskaya I; Kovalevska L; Ose V; Priede D; Pumpens P; Sasnauskas K
Vaccine; 2008 Apr; 26(16):1972-81. PubMed ID: 18343539
[TBL] [Abstract][Full Text] [Related]
28. Hepatitis B virus core-preS2 particles expressed by recombinant vaccinia virus.
Nemecková S; Sroller V; Kunke D; Krystofová J; Kutinová L
Acta Virol; 1996; 40(5-6):273-9. PubMed ID: 9171455
[TBL] [Abstract][Full Text] [Related]
29. Development of recombinant Salmonellae expressing hybrid hepatitis B virus core particles as candidate oral vaccines.
Schödel F; Kelly SM; Peterson D; Milich D; Hughes J; Tinge S; Wirtz R; Curtiss R
Dev Biol Stand; 1994; 82():151-8. PubMed ID: 7958469
[TBL] [Abstract][Full Text] [Related]
30. Efficient induction of human T-cell leukemia virus-1-specific CTL by chimeric particle without adjuvant as a prophylactic for adult T-cell leukemia.
Kozako T; Fukada K; Hirata S; White Y; Harao M; Nishimura Y; Kino Y; Soeda S; Shimeno H; Lemonnier F; Sonoda S; Arima N
Mol Immunol; 2009 Dec; 47(2-3):606-13. PubMed ID: 19889459
[TBL] [Abstract][Full Text] [Related]
31. Development of highly sensitive Bicistronic vector based non-radioactive antigen-specific cytotoxicity assay.
Gupta P; Tayal R; Durgapal H; Rath S; Acharya SK; Panda SK
J Immunol Methods; 2009 Sep; 349(1-2):28-37. PubMed ID: 19682994
[TBL] [Abstract][Full Text] [Related]
32. A hepatitis B virus core antigen-based virus-like particle vaccine expressing SARS-CoV-2 B and T cell epitopes induces epitope-specific humoral and cell-mediated immune responses but confers limited protection against SARS-CoV-2 infection.
Hassebroek AM; Sooryanarain H; Heffron CL; Hawks SA; LeRoith T; Cecere TE; Stone WB; Walter D; Mahsoub HM; Wang B; Tian D; Ivester HM; Allen IC; Auguste AJ; Duggal NK; Zhang C; Meng XJ
J Med Virol; 2023 Feb; 95(2):e28503. PubMed ID: 36655751
[TBL] [Abstract][Full Text] [Related]
33. Chimeric (mouse/human) anti-colon cancer antibody c30.6 inhibits the growth of human colorectal cancer xenografts in scid/scid mice.
Mount PF; Sutton VR; Li W; Burgess J; McKEnzie IF; Pietersz GA; Trapani JA
Cancer Res; 1994 Dec; 54(23):6160-6. PubMed ID: 7954462
[TBL] [Abstract][Full Text] [Related]
34. Claudin-18 gene structure, regulation, and expression is evolutionary conserved in mammals.
Türeci O; Koslowski M; Helftenbein G; Castle J; Rohde C; Dhaene K; Seitz G; Sahin U
Gene; 2011 Aug; 481(2):83-92. PubMed ID: 21571049
[TBL] [Abstract][Full Text] [Related]
35. Hepatitis B surface antigen vector delivers protective cytotoxic T-lymphocyte responses to disease-relevant foreign epitopes.
Woo WP; Doan T; Herd KA; Netter HJ; Tindle RW
J Virol; 2006 Apr; 80(8):3975-84. PubMed ID: 16571814
[TBL] [Abstract][Full Text] [Related]
36. [Humoral and cellular immunogenecity of genetic vaccine on core gene of hepatitis B virus in mice].
Huang Z; Lu S; Liu N
Zhonghua Yi Xue Za Zhi; 1999 Jun; 79(6):456-9. PubMed ID: 11715443
[TBL] [Abstract][Full Text] [Related]
37. Characterization of complex B cell epitopes on woodchuck hepatitis virus surface antigens by using plasmids encoding chimeric proteins and DNA immunization.
Zheng X; Schirmbeck R; Hilken G; Waters JA; Yang D; Reimann J; Roggendorf M; Lu M
Virology; 2002 Mar; 294(2):342-53. PubMed ID: 12009876
[TBL] [Abstract][Full Text] [Related]
38. In vivo plasmid electroporation induces tumor antigen-specific CD8+ T-cell responses and delays tumor growth in a syngeneic mouse melanoma model.
Kalat M; Küpcü Z; Schüller S; Zalusky D; Zehetner M; Paster W; Schweighoffer T
Cancer Res; 2002 Oct; 62(19):5489-94. PubMed ID: 12359758
[TBL] [Abstract][Full Text] [Related]
39. Antibody production to the nucleocapsid and envelope of the hepatitis B virus primed by a single synthetic T cell site.
Milich DR; McLachlan A; Thornton GB; Hughes JL
Nature; 1987 Oct 8-14; 329(6139):547-9. PubMed ID: 2443856
[TBL] [Abstract][Full Text] [Related]
40. Immunization of BALB/c mice with recombinant simian virus 40 large tumor antigen induces antibody-dependent cell-mediated cytotoxicity against simian virus 40-transformed cells. An antibody-based mechanism for tumor immunity.
Bright RK; Shearer MH; Kennedy RC
J Immunol; 1994 Sep; 153(5):2064-71. PubMed ID: 8051411
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
